OSR Holdings Inc
OSRH
查看详细走势图
0.550USD
+0.036+6.94%
收盘 02/06, 16:00（美东）报价延迟15分钟
13.02M总市值
0.19市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+6.94%
5天
-5.82%
1月
-12.56%
6月
-11.15%
今年开始到现在
-2.50%
1年
-95.10%
查看详细走势图
TradingKey OSR Holdings Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
OSR Holdings Inc当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名186/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价10.00。中期看，股价处于平稳状态。近一个月，市场表现非常差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
OSR Holdings Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
OSR Holdings Inc亮点
亮点风险
OSR Holdings, Inc. is a global healthcare company, dedicated to advancing healthcare outcomes and improving the quality of life for people and their families. The Company is focused on building and developing a portfolio of transformative therapies and healthcare solutions. The Company's operating businesses (through its three wholly owned subsidiaries) include developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases and neurovascular intervention medical device and systems distribution in Korea. The Company’s subsidiary, Vaximm’s flagship asset, VXM01, is a late clinical-stage (NCT037500701) immuno-oncology candidate for glioblastoma. Vaximm has three clinical and pre-clinical drug candidates targeting diseases ranging from glioblastoma to gastrointestinal stromal tumor to ocular diseases. The Company has operations in Europe and South Korea.
利润高增长
公司净利润处于行业前列，最新年度总收入0.00美元
业绩转亏
公司业绩转亏，最新年度亏损美元
估值高估
公司最新PE估值0.19，处于3年历史高位
机构减仓
最新机构持股236.43K股，环比减少93.35%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值54.40K
分析师目标
根据
1
位分析师
买入
评级
10.000
目标均价
+1627.41%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
OSR Holdings Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
OSR Holdings Inc简介
OSR Holdings, Inc. is a global healthcare company, dedicated to advancing healthcare outcomes and improving the quality of life for people and their families. The Company is focused on building and developing a portfolio of transformative therapies and healthcare solutions. The Company's operating businesses (through its three wholly owned subsidiaries) include developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases and neurovascular intervention medical device and systems distribution in Korea. The Company’s subsidiary, Vaximm’s flagship asset, VXM01, is a late clinical-stage (NCT037500701) immuno-oncology candidate for glioblastoma. Vaximm has three clinical and pre-clinical drug candidates targeting diseases ranging from glioblastoma to gastrointestinal stromal tumor to ocular diseases. The Company has operations in Europe and South Korea.
公司代码OSRH
公司OSR Holdings Inc
CEOHwang (Kuk Hyoun)
网址https://osr-holdings.com/
相关品种
